Ikena Oncology (NASDAQ:IKNA) Stock Rating Reaffirmed by William Blair

Ikena Oncology (NASDAQ:IKNA)‘s stock had its “outperform” rating restated by William Blair in a research report issued to clients and investors on Thursday, RTT News reports.

Several other equities analysts have also recently commented on IKNA. Wedbush initiated coverage on shares of Ikena Oncology in a research report on Thursday, September 21st. They set an “outperform” rating and a $11.00 target price on the stock. HC Wainwright dropped their target price on shares of Ikena Oncology from $18.00 to $11.00 and set a “buy” rating on the stock in a research report on Thursday, November 9th.

Ikena Oncology Stock Performance

Shares of NASDAQ IKNA opened at $1.80 on Thursday. Ikena Oncology has a fifty-two week low of $1.02 and a fifty-two week high of $7.64. The stock has a market cap of $76.14 million, a price-to-earnings ratio of -1.11 and a beta of 0.78. The firm’s 50-day simple moving average is $3.72 and its 200 day simple moving average is $5.12.

Institutional Trading of Ikena Oncology

Several hedge funds have recently added to or reduced their stakes in IKNA. JPMorgan Chase & Co. raised its position in Ikena Oncology by 25.4% in the first quarter. JPMorgan Chase & Co. now owns 17,172 shares of the company’s stock worth $104,000 after acquiring an additional 3,482 shares during the period. BlackRock Inc. raised its stake in shares of Ikena Oncology by 9.5% during the 1st quarter. BlackRock Inc. now owns 1,493,161 shares of the company’s stock valued at $9,108,000 after purchasing an additional 129,284 shares during the period. Vanguard Group Inc. raised its stake in shares of Ikena Oncology by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 789,999 shares of the company’s stock valued at $4,819,000 after purchasing an additional 7,605 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Ikena Oncology by 5.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 66,810 shares of the company’s stock valued at $408,000 after purchasing an additional 3,276 shares during the period. Finally, State Street Corp raised its stake in shares of Ikena Oncology by 18.8% during the 1st quarter. State Street Corp now owns 404,602 shares of the company’s stock valued at $2,468,000 after purchasing an additional 63,988 shares during the period. Institutional investors own 86.01% of the company’s stock.

About Ikena Oncology

Ikena Oncology, Inc operates as an oncology company that develops precision medicines to biomarker-defined patients with specific unmet needs in the United States. Its lead oncology product candidate is IK-930, a paralog selective inhibitor of the transcriptional enhanced associate domain, a transcription factor in the Hippo signaling pathway.